| Regal Asian Investments Limited (RG8) ORDINARY FULLY PAID |
Financials |
$391 |
Update - Notification of buy-back - RG8
|
20 Nov 2025 9:07AM |
$2.380 |
$2.780 |
risen by
16.81%
|
|
| Greenwing Resources Ltd (GW1) ORDINARY FULLY PAID |
Materials |
$46 |
San Jorge Lithium Project - Update
|
20 Nov 2025 9:06AM |
$0.031 |
$0.089 |
risen by
187.10%
|
|
| Raiz Invest Limited (RZI) ORDINARY FULLY PAID |
Financials |
$64 |
Results of Meeting
|
20 Nov 2025 9:06AM |
$0.868 |
$0.605 |
fallen by
30.26%
|
|
| CVC Limited (CVC) ORDINARY FULLY PAID |
Financials |
$192 |
Early Redemption Notice CVC Notes 2
|
20 Nov 2025 9:06AM |
$2.070 |
$1.650 |
fallen by
20.29%
|
|
CVC - Price-sensitive ASX Announcement
Full Release
Key Points
- CVC Limited issues Redemption Notice for CVC Notes 2.
- Redemption Date set for 10 December 2025.
- Holders may reinvest in CVC Notes 3 or redeem their notes.
- Redemption includes $100 per note, $2 premium, and final interest payment.
- Last trading day for CVCHA on ASX is 28 November 2025.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| VGI Partners Global Investments Limited (VG1) ORDINARY FULLY PAID |
Financials |
- |
Update - Notification of buy-back - VG1
|
20 Nov 2025 9:05AM |
$1.975 |
$1.950 |
fallen by
1.27%
|
|
| Guzman Y Gomez Limited (GYG) ORDINARY FULLY PAID |
Consumer Discretionary |
$2,387 |
Update - Notification of buy-back - GYG
|
20 Nov 2025 9:05AM |
$21.990 |
$23.970 |
risen by
9%
|
|
| Dexus Industria REIT (DXI) FULLY PAID ORDINARY/UNITS STAPLED SECURITIES |
Real Estate |
$741 |
2025 AGM Chair and Fund Manager address
|
20 Nov 2025 9:05AM |
$2.760 |
$2.370 |
fallen by
14.13%
|
|
| Qube Holdings Limited (QUB) ORDINARY FULLY PAID |
Industrials |
$9,117 |
Chairman's Address and Managing Director's Presentation
|
20 Nov 2025 9:04AM |
$4.180 |
$5.110 |
risen by
22.25%
|
|
QUB - Price-sensitive ASX Announcement
Full Release
Key Points
- Qube Holdings Limited demonstrated significant growth in FY25, with underlying revenue increasing by 27% compared to FY24.
- The company's EBITA also grew by 18.5%, and underlying earnings per share rose by 6.0% to 16.25 cents.
- Qube's diversified business model enabled resilience against challenges such as industrial action and extreme weather.
- Strategic acquisitions, including the acquisition of Coleman in Western Australia, supported entry into new markets like the SSAN supply market.
- Qube enhanced its financial strength with investment-grade credit ratings and increased its full-year dividend by 7.1% to 9.8 cents per share.
- Safety remains a top priority, with mixed results in safety performance metrics but overall improvements in safety culture through the QUBESAFE program.
- The Chairman, Allan Davies, announced his retirement after serving for 14 years, with John Bevan elected as his successor.
- Qube's performance and positive outlook enabled them to maintain a strong position in the market, emphasizing both organic and inorganic growth opportunities.
- The company made divestments totaling around $248 million, primarily from the sale of a property at Minto.
- Qube's board also underwent changes, with new members bringing extensive experience to further the company's goals.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Whitehaven Coal Limited (WHC) ORDINARY FULLY PAID |
Energy |
$6,274 |
Update - Notification of buy-back - WHC
|
20 Nov 2025 9:03AM |
$7.000 |
$7.630 |
risen by
9%
|
|
| Orthocell Limited (OCC) ORDINARY FULLY PAID |
Health Care |
$227 |
Remplir gains momentum in nerve-sparing prostate surgery
|
20 Nov 2025 9:03AM |
$1.005 |
$0.835 |
fallen by
16.92%
|
|
OCC - Price-sensitive ASX Announcement
Full Release
Key Points
- Remplirâ„¢ adoption by Australian urologists for nerve-sparing prostate surgery is accelerating.
- Approximately 100 surgeries conducted using Remplir to improve postoperative nerve function.
- Remplir aims to reduce complications such as erectile dysfunction and urinary incontinence post-surgery.
- Remplir has potential to expand the U.S. market from $1.6 billion to approximately $2 billion.
- Orthocell is investing in further research to support a U.S. launch.
- Initial clinical data from Australia will support international market launches.
- Remplir is well-positioned for expansion into new surgical specialties.
- Orthocell is financially positioned with $50 million in cash and no debt for rapid product adoption.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Dart Mining NL (DTM) ORDINARY FULLY PAID |
Materials |
$3 |
Triumph Drilling Continues to Widen New Constitution
|
20 Nov 2025 9:00AM |
$0.033 |
$0.010 |
fallen by
69.70%
|
|
DTM - Price-sensitive ASX Announcement
Full Release
Key Points
- Continued drilling at New Constitution expands mineralization.
- Significant intersections indicate promising mineral quantities.
- Focus on expanding resource base and project value.
- Emphasis on enhancing shareholder value through exploration.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Qualitas Real Estate Income Fund (QRI) ORDINARY UNITS FULLY PAID |
Financials |
$969 |
Cleansing Notice
|
20 Nov 2025 9:00AM |
$1.590 |
$1.535 |
fallen by
3.46%
|
|
| Sonic Healthcare Limited (SHL) ORDINARY FULLY PAID |
Health Care |
$10,567 |
2025 AGM CEO Presentations and Proxy Summary
|
20 Nov 2025 8:59AM |
$21.490 |
$21.380 |
fallen by
0.51%
|
|
SHL - Price-sensitive ASX Announcement
Full Release
Key Points
- Sonic Healthcare achieved an 8% increase in revenue and EBITDA for FY 2025.
- Key markets include the USA, Australia, Germany, and Switzerland.
- Acquisition of LADR Laboratory Group in Germany is a strategic growth move.
- The company emphasizes high-value medicine to drive growth.
- Sonic focuses on enhancing shareholder value through disciplined capital allocation.
- Sustainability initiatives include significant emission reductions and renewable energy commitment.
- FY 2026 guidance projects up to 13% EBITDA growth.
- Investment in medical excellence and innovation continues.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| CVC Limited (CVC) ORDINARY FULLY PAID |
Financials |
$192 |
Update - Proposed issue of securities - CVC
|
20 Nov 2025 8:59AM |
$2.070 |
$1.650 |
fallen by
20.29%
|
|
| New Hope Corporation Limited (NHC) ORDINARY FULLY PAID |
Energy |
$4,776 |
2025 AGM Addresses and Presentation
|
20 Nov 2025 8:58AM |
$4.040 |
$5.660 |
risen by
40.10%
|
|
| CVC Limited (CVC) ORDINARY FULLY PAID |
Financials |
$192 |
CVC Notes 3 Replacement Prospectus
|
20 Nov 2025 8:57AM |
$2.070 |
$1.650 |
fallen by
20.29%
|
|
CVC - Price-sensitive ASX Announcement
Full Release
Key Points
- CVC Notes 3 are redeemable, unsecured, non-convertible, unsubordinated notes.
- The offer comprises a New Money Offer and a Reinvestment Offer.
- CVC Notes 3 have a face value of $100 with a 4.50% margin over the 3-month BBSW.
- Expected maturity date is 11 December 2028.
- The offering aims to raise $75 million.
- CVC Notes 3 rank ahead of ordinary shares in liquidation.
- Proceeds are for corporate purposes and investment opportunities.
- Managed by E&P Capital Pty Limited as Lead Manager.
- Speculative investment with professional advice recommended.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Radiopharm Theranostics Limited (RAD) ORDINARY FULLY PAID |
Health Care |
$43 |
Presentation to Annual General Meeting
|
20 Nov 2025 8:57AM |
$0.022 |
$0.010 |
fallen by
54.55%
|
|
| American West Metals Limited (AW1) ORDINARY FULLY PAID |
Materials |
$45 |
Corporate Presentation
|
20 Nov 2025 8:56AM |
$0.054 |
$0.037 |
fallen by
31.48%
|
|
| Sonic Healthcare Limited (SHL) ORDINARY FULLY PAID |
Health Care |
$10,567 |
Chairman's Address to Shareholders
|
20 Nov 2025 8:55AM |
$21.490 |
$21.380 |
fallen by
0.51%
|
|
| GCM Corporation Limited (GCM) ORDINARY FULLY PAID |
Materials |
$23 |
VHD Thermal Conductivity Superior Performance Validated
|
20 Nov 2025 8:54AM |
$0.013 |
$0.120 |
risen by
823.08%
|
|
GCM - Price-sensitive ASX Announcement
Full Release
Key Points
- VHD technology delivers superior thermal conductivity and diffusivity compared to copper and aluminum.
- VHD's thermal conductivity is 1.3x that of copper and 3x that of aluminum.
- VHD's thermal diffusivity is 2.9x that of copper and 4.6x that of aluminum.
- These results confirm VHD as a leading thermal management product.
- GCM targets first revenue from VHD in the first half of 2026.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| BlueScope Steel Limited (BSL) ORDINARY FULLY PAID |
Materials |
$13,164 |
Update - Notification of buy-back - BSL
|
20 Nov 2025 8:53AM |
$22.610 |
$30.050 |
risen by
32.91%
|
|
| Norwest Minerals Limited (NWM) ORDINARY FULLY PAID |
Materials |
$12 |
Bulgera drilling underway
|
20 Nov 2025 8:53AM |
$0.011 |
$0.009 |
fallen by
18.18%
|
|
| Block, Inc. (XYZ) CDI 1:1 FOREIGN EXEMPT NYSE |
Financials |
$4,364 |
Form 8-K - Share Repurchase Authorization
|
20 Nov 2025 8:52AM |
$88.510 |
$115.020 |
risen by
29.95%
|
|
| PhosCo Ltd (PHO) ORDINARY FULLY PAID |
Materials |
$76 |
Investor Update Presentation - November 2025
|
20 Nov 2025 8:52AM |
$0.120 |
$0.140 |
risen by
16.67%
|
|
| Ventia Services Group Limited (VNT) ORDINARY FULLY PAID |
Industrials |
$4,572 |
Update - Notification of buy-back - VNT
|
20 Nov 2025 8:51AM |
$5.520 |
$5.590 |
risen by
1.27%
|
|